Bristol-Myers Squibb (BMY)

The Dividend Harvesting Portfolio rebounded strongly, with profitability up 8.06% and total dividend income now at 19.77% of invested capital. I remain bullish on the S&P 500 reaching 7,000 this year,...

Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Investing in high-yielding dividend stocks can result in significant dividend income for your portfolio. But higher yields also tend to mean higher risk, and dividends are never guaranteed.

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li...

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused ...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).

Bristol-Myers Squibb faces political pressure on U.S. drug prices, but I see the risk as manageable given its strong fundamentals. The company's growth portfolio now exceeds half of revenue, offsettin...

Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum. Despite margin compression and profitability con...